A common clinical dilemma

Management of abnormal vaginal cytology and human papillomavirus test results

Michelle J. Khan, L. Stewart Massad, Walter Kinney, Michael A. Gold, Ej Mayeaux, Teresa M. Darragh, Philip E. Castle, David Chelmow, Herschel W. Lawson, Warner K. Huh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

After hysterectomy, HSIL and cancer of the vagina are rare; we propose a conservative approach to management of abnormal vaginal cytology and/or high-risk HPV tests. Supplemental digital content is available in the text. Objective Vaginal cancer is an uncommon cancer of the lower genital tract, and standardized screening is not recommended. Risk factors for vaginal cancer include a history of other lower genital tract neoplasia or cancer, smoking, immunosuppression, and exposure to diethylstilbestrol in utero. Although cervical cancer screening after total hysterectomy for benign disease is not recommended, many women inappropriately undergo vaginal cytology and/or human papillomavirus (HPV) tests, and clinicians are faced with managing their abnormal results. Our objectives were to review the literature on vaginal cytology and high-risk HPV (hrHPV) testing and to develop guidance for the management of abnormal vaginal screening tests. Materials and Methods An electronic search of the PubMed database through 2015 was performed. Articles describing vaginal cytology or vaginal hrHPV testing were reviewed, and diagnostic accuracy of these tests when available was noted. Results The available literature was too limited to develop evidence-based recommendations for managing abnormal vaginal cytology and hrHPV screening tests. However, the data did show that (1) the risk of vaginal cancer in women after hysterectomy is extremely low, justifying the recommendation against routine screening, and (2) in women for whom surveillance is recommended, e.g., women posttreatment for cervical precancer or cancer, hrHPV testing may be useful in identification of vaginal cancer precursors. Conclusions Vaginal cancer is rare, and asymptomatic low-risk women should not be screened. An algorithm based on expert opinion is proposed for managing women with abnormal vaginal test results.

Original languageEnglish (US)
Pages (from-to)119-125
Number of pages7
JournalJournal of Lower Genital Tract Disease
Volume20
Issue number2
DOIs
StatePublished - Apr 1 2016

Fingerprint

Vaginal Neoplasms
Cell Biology
Hysterectomy
Neoplasms
Diethylstilbestrol
Expert Testimony
Early Detection of Cancer
Routine Diagnostic Tests
PubMed
Uterine Cervical Neoplasms
Immunosuppression
Smoking
Databases

Keywords

  • HPV
  • vaginal cancer
  • vaginal cytology
  • VaIN

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Khan, M. J., Massad, L. S., Kinney, W., Gold, M. A., Mayeaux, E., Darragh, T. M., ... Huh, W. K. (2016). A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Journal of Lower Genital Tract Disease, 20(2), 119-125. https://doi.org/10.1097/LGT.0000000000000185

A common clinical dilemma : Management of abnormal vaginal cytology and human papillomavirus test results. / Khan, Michelle J.; Massad, L. Stewart; Kinney, Walter; Gold, Michael A.; Mayeaux, Ej; Darragh, Teresa M.; Castle, Philip E.; Chelmow, David; Lawson, Herschel W.; Huh, Warner K.

In: Journal of Lower Genital Tract Disease, Vol. 20, No. 2, 01.04.2016, p. 119-125.

Research output: Contribution to journalArticle

Khan, MJ, Massad, LS, Kinney, W, Gold, MA, Mayeaux, E, Darragh, TM, Castle, PE, Chelmow, D, Lawson, HW & Huh, WK 2016, 'A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results', Journal of Lower Genital Tract Disease, vol. 20, no. 2, pp. 119-125. https://doi.org/10.1097/LGT.0000000000000185
Khan, Michelle J. ; Massad, L. Stewart ; Kinney, Walter ; Gold, Michael A. ; Mayeaux, Ej ; Darragh, Teresa M. ; Castle, Philip E. ; Chelmow, David ; Lawson, Herschel W. ; Huh, Warner K. / A common clinical dilemma : Management of abnormal vaginal cytology and human papillomavirus test results. In: Journal of Lower Genital Tract Disease. 2016 ; Vol. 20, No. 2. pp. 119-125.
@article{909080132aaa4591b08013a814eb28fe,
title = "A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results",
abstract = "After hysterectomy, HSIL and cancer of the vagina are rare; we propose a conservative approach to management of abnormal vaginal cytology and/or high-risk HPV tests. Supplemental digital content is available in the text. Objective Vaginal cancer is an uncommon cancer of the lower genital tract, and standardized screening is not recommended. Risk factors for vaginal cancer include a history of other lower genital tract neoplasia or cancer, smoking, immunosuppression, and exposure to diethylstilbestrol in utero. Although cervical cancer screening after total hysterectomy for benign disease is not recommended, many women inappropriately undergo vaginal cytology and/or human papillomavirus (HPV) tests, and clinicians are faced with managing their abnormal results. Our objectives were to review the literature on vaginal cytology and high-risk HPV (hrHPV) testing and to develop guidance for the management of abnormal vaginal screening tests. Materials and Methods An electronic search of the PubMed database through 2015 was performed. Articles describing vaginal cytology or vaginal hrHPV testing were reviewed, and diagnostic accuracy of these tests when available was noted. Results The available literature was too limited to develop evidence-based recommendations for managing abnormal vaginal cytology and hrHPV screening tests. However, the data did show that (1) the risk of vaginal cancer in women after hysterectomy is extremely low, justifying the recommendation against routine screening, and (2) in women for whom surveillance is recommended, e.g., women posttreatment for cervical precancer or cancer, hrHPV testing may be useful in identification of vaginal cancer precursors. Conclusions Vaginal cancer is rare, and asymptomatic low-risk women should not be screened. An algorithm based on expert opinion is proposed for managing women with abnormal vaginal test results.",
keywords = "HPV, vaginal cancer, vaginal cytology, VaIN",
author = "Khan, {Michelle J.} and Massad, {L. Stewart} and Walter Kinney and Gold, {Michael A.} and Ej Mayeaux and Darragh, {Teresa M.} and Castle, {Philip E.} and David Chelmow and Lawson, {Herschel W.} and Huh, {Warner K.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1097/LGT.0000000000000185",
language = "English (US)",
volume = "20",
pages = "119--125",
journal = "Journal of Lower Genital Tract Disease",
issn = "1089-2591",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A common clinical dilemma

T2 - Management of abnormal vaginal cytology and human papillomavirus test results

AU - Khan, Michelle J.

AU - Massad, L. Stewart

AU - Kinney, Walter

AU - Gold, Michael A.

AU - Mayeaux, Ej

AU - Darragh, Teresa M.

AU - Castle, Philip E.

AU - Chelmow, David

AU - Lawson, Herschel W.

AU - Huh, Warner K.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - After hysterectomy, HSIL and cancer of the vagina are rare; we propose a conservative approach to management of abnormal vaginal cytology and/or high-risk HPV tests. Supplemental digital content is available in the text. Objective Vaginal cancer is an uncommon cancer of the lower genital tract, and standardized screening is not recommended. Risk factors for vaginal cancer include a history of other lower genital tract neoplasia or cancer, smoking, immunosuppression, and exposure to diethylstilbestrol in utero. Although cervical cancer screening after total hysterectomy for benign disease is not recommended, many women inappropriately undergo vaginal cytology and/or human papillomavirus (HPV) tests, and clinicians are faced with managing their abnormal results. Our objectives were to review the literature on vaginal cytology and high-risk HPV (hrHPV) testing and to develop guidance for the management of abnormal vaginal screening tests. Materials and Methods An electronic search of the PubMed database through 2015 was performed. Articles describing vaginal cytology or vaginal hrHPV testing were reviewed, and diagnostic accuracy of these tests when available was noted. Results The available literature was too limited to develop evidence-based recommendations for managing abnormal vaginal cytology and hrHPV screening tests. However, the data did show that (1) the risk of vaginal cancer in women after hysterectomy is extremely low, justifying the recommendation against routine screening, and (2) in women for whom surveillance is recommended, e.g., women posttreatment for cervical precancer or cancer, hrHPV testing may be useful in identification of vaginal cancer precursors. Conclusions Vaginal cancer is rare, and asymptomatic low-risk women should not be screened. An algorithm based on expert opinion is proposed for managing women with abnormal vaginal test results.

AB - After hysterectomy, HSIL and cancer of the vagina are rare; we propose a conservative approach to management of abnormal vaginal cytology and/or high-risk HPV tests. Supplemental digital content is available in the text. Objective Vaginal cancer is an uncommon cancer of the lower genital tract, and standardized screening is not recommended. Risk factors for vaginal cancer include a history of other lower genital tract neoplasia or cancer, smoking, immunosuppression, and exposure to diethylstilbestrol in utero. Although cervical cancer screening after total hysterectomy for benign disease is not recommended, many women inappropriately undergo vaginal cytology and/or human papillomavirus (HPV) tests, and clinicians are faced with managing their abnormal results. Our objectives were to review the literature on vaginal cytology and high-risk HPV (hrHPV) testing and to develop guidance for the management of abnormal vaginal screening tests. Materials and Methods An electronic search of the PubMed database through 2015 was performed. Articles describing vaginal cytology or vaginal hrHPV testing were reviewed, and diagnostic accuracy of these tests when available was noted. Results The available literature was too limited to develop evidence-based recommendations for managing abnormal vaginal cytology and hrHPV screening tests. However, the data did show that (1) the risk of vaginal cancer in women after hysterectomy is extremely low, justifying the recommendation against routine screening, and (2) in women for whom surveillance is recommended, e.g., women posttreatment for cervical precancer or cancer, hrHPV testing may be useful in identification of vaginal cancer precursors. Conclusions Vaginal cancer is rare, and asymptomatic low-risk women should not be screened. An algorithm based on expert opinion is proposed for managing women with abnormal vaginal test results.

KW - HPV

KW - vaginal cancer

KW - vaginal cytology

KW - VaIN

UR - http://www.scopus.com/inward/record.url?scp=84959170920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959170920&partnerID=8YFLogxK

U2 - 10.1097/LGT.0000000000000185

DO - 10.1097/LGT.0000000000000185

M3 - Article

VL - 20

SP - 119

EP - 125

JO - Journal of Lower Genital Tract Disease

JF - Journal of Lower Genital Tract Disease

SN - 1089-2591

IS - 2

ER -